REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Clinical trials for REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR trials appear
Sign up with your email to follow new studies for REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…
Matched conditions: REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control OngoingThis study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…
Matched conditions: REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:42 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…
Matched conditions: REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Targeted drug tipifarnib tested in kids with rare HRAS-Driven cancers
Disease control OngoingThis study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…
Matched conditions: REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Gene-Guided hope: pediatric MATCH trial aims to outsmart tough childhood cancers
Knowledge-focused OngoingThis study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…
Matched conditions: REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC